Oxford Nanopore (LON: ONT) and Lonza Launch Direct RNA Sequencing Solution for GMP mRNA Quality Control

Oxford Nanopore (LON: ONT) and Lonza Launch Direct RNA Sequencing Solution for GMP mRNA Quality Control

Oxford Nanopore Technologies (LON: ONT) and Lonza have launched a direct RNA sequencing solution designed for use in GMP-grade quality control testing of mRNA products, completing a development programme that began in early 2024 and represents the first commercially available multi-attribute QC method for mRNA therapies designed to function within a regulated manufacturing environment. The solution, built on Oxford Nanopore’s direct sequencing t…

Lonza and Oxford Nanopore Technologies Launch Direct RNA Sequencing Solution for GMP mRNA Quality Control

“By integrating Oxford Nanopore’s direct RNA sequencing into Lonza’s QC environment, we are enabling a more comprehensive and scalable approach to mRNA quality control,” said Francis Van Parys, CEO, Oxford Nanopore Technologies The post Lonza and Oxford Nanopore Technologies Launch Direct RNA Sequencing Solution for GMP mRNA Quality Control first appeared on Medical Device News Magazine.